Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents

被引：0
|
作者：
Jean-Marc Barret
Anna Kruczynski
Chantal Etiévant
Bridget T. Hill
机构：
[1] Division de Cancérologie,
[2] Centre de Recherche Pierre Fabre,undefined
[3] 17 avenue Jean Moulin,undefined
[4] 81100 Castres,undefined
[5] France,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2002年 / 49卷
关键词：
F 11782 Combination index Synergy Cultured cells In vivo;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：479 / 486
页数：7
相关论文
共 50 条
  • [31] Antitumor activity of LB42907, a potent and selective farnesyltransferase inhibitor: Synergistic effect in combination with other anticancer drugs
    Park, Ji Hyun
    Koo, Sun-Young
    Kim, Dong-Myung
    Kim, Kwihwa
    Jeong, Shin Wu
    Chung, Hyun-Ho
    Cho, Heung-Soo
    Park, Joonghoon
    Yim, Hyeon Joo
    Lee, Jinho
    Koh, Jong Sung
    Kim, Semi
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2008, 29 (07) : 1303 - 1310
  • [32] Seamless phase I/II design for novel anticancer agents with competing disease progression
    Biard, Lucie
    Lee, Shing M.
    Cheng, Bin
    STATISTICS IN MEDICINE, 2021, 40 (21) : 4568 - 4581
  • [33] Phase I and II evaluation of novel anticancer agents: Are response and toxicity the right endpoints?
    Eisenhauer, EA
    ONKOLOGIE, 2000, 23 : 2 - 6
  • [34] Synthesis of novel naphthoquinone-spermidine conjugates and their effects on DNA-topoisomerases I and II-α
    Cunha, Andrea S.
    Lima, Edson L. S.
    Pinto, Angelo C.
    Esteves-Souza, Andressa
    Echevarria, Aurea
    Camara, Celso A.
    Vargas, Maria D.
    Torres, Jose C.
    JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY, 2006, 17 (03) : 439 - 442
  • [35] Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II
    Utsugi, T
    Aoyagi, K
    Asao, T
    Okazaki, S
    Aoyagi, Y
    Sano, M
    Wierzba, K
    Yamada, Y
    JAPANESE JOURNAL OF CANCER RESEARCH, 1997, 88 (10): : 992 - 1002
  • [36] PNU 157706, a novel dual type I and II 5α-reductase inhibitor
    di Salle, E
    Giudici, D
    Radice, A
    Zaccheo, T
    Ornati, G
    Nesi, M
    Panzeri, A
    Délos, S
    Martin, PM
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1998, 64 (3-4): : 179 - 186
  • [37] XR11576, a novel dual inhibitor of topoisomerase I and II.
    Dangerfield, W
    Stewart, A
    Kofler, B
    Smith, L
    Okiji, S
    Charlton, P
    CLINICAL CANCER RESEARCH, 2000, 6 : 4516S - 4516S
  • [38] EFFECTS OF AMSACRINE IN COMBINATION WITH OTHER ANTICANCER AGENTS IN HUMAN ACUTE LYMPHOBLASTIC-LEUKEMIA CELLS IN CULTURE
    KANO, Y
    SAKAMOTO, S
    KASAHARA, T
    AKUTSU, M
    INOUE, Y
    MIURA, Y
    LEUKEMIA RESEARCH, 1991, 15 (11) : 1059 - 1066
  • [39] Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects againstMYCN-amplified neuroblastoma
    Tee, Andrew E.
    Ciampa, Olivia C.
    Wong, Matthew
    Fletcher, Jamie I.
    Kamili, Alvin
    Chen, Jingwei
    Ho, Nicholas
    Sun, Yuting
    Carter, Daniel R.
    Cheung, Belamy B.
    Marshall, Glenn M.
    Liu, Pei Y.
    Liu, Tao
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (07) : 1928 - 1938
  • [40] Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer
    Sargent, JM
    Elgie, AW
    Williamson, CJ
    Hill, BT
    ANTI-CANCER DRUGS, 2003, 14 (06) : 467 - 473
12345